CompletedInterventionalPhase 4Updated Dec 18, 2012
A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis | NCT01470118 | Trialant
CompletedInterventionalPhase 4Updated Feb 21, 2013
A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis
ClinicalTrials.gov ID
NCT01470118
Lead Sponsor
AllerganINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 4
Enrollment
127Actual
Last Update Posted
Feb 21, 2013Estimated
Start Date
Oct 2011
Primary Completion Date
Dec 2011Actual
Completion Date
Dec 2011Actual
Brief Summary
This study will evaluate the duration of action of LASTACAFT® and Pataday™ as compared to artificial tears (placebo) in the prevention of ocular itching associated with allergic conjunctivitis.